Curevo’s CEO, George Simeon, will discuss updated data from Curevo’s 876-patient head-to-head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix ®.
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s ...